Evaluation of Renal Impairment Influence on Metabolic Drug Clearance using a Modelling Approach
Tóm tắt
Chronic kidney disease (CKD) may alter drug renal elimination but is also known for interacting with hepatic metabolism via multiple uremic components. However, few global models, considering the five major cytochromes, have been published, and none specifically address the decrease in cytochrome P450 (CYP450) activity. The aim of our study was to estimate the possibility of quantifying residual cytochrome activity as a function of filtration rate, according to the data available in the literature. For each drug in the DDI-predictor database, we collected available pharmacokinetic data comparing drug exposition in the healthy patient and in various stages of CKD, before building a model capable of predicting the variation of exposure according to the degree of renal damage. We followed an In vivo Mechanistic Static Model (IMSM) approach, previously validated for predicting change in liver clearance. We estimated the remaining fraction parameters at glomerular filtration rate (GFR) = 0 and the alpha value of GFR to 50% impairment for the 5 major cytochromes using a non-linear constrained regression using Matlab software. Thirty-one compounds had usable pharmacokinetic data, with 51 AUC ratios between healthy and renal impaired patients. The remaining CYP3A4 activity was estimated to be 0.4 when CYP2D6, 2C9, 2C19 and 1A2 activity was estimated to be 0.43; 1; 0.73 and 0.7, respectively. The alpha value was estimated to be at 6.62; 25; 9.8; 1.38 and 11.04 for each cytochrome. In comparison with published data, all estimates but one were correctly predicted in the range of 0.5–2. Our approach was able to describe the impact of CKD on metabolic elimination. Modelling this process makes it possible to anticipate changes in clearance and drug exposure in CKD patients, with the advantage of greater simplicity than approaches based on physiologically-based pharmacokinetic modelling. However, a precise estimation of the impact of renal failure is not possible with an IMSM approach due to the large variability of the published data, and thus should rely on specific pharmacokinetic modelling for narrow therapeutic margin drugs.
Tài liệu tham khảo
Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2020;395:709–33.
Meier P, Saudan P, Burnier M, Martin PY. Comorbidité et facteurs de risque cardiovasculaire liés à l’insuffisance rénale chronique. Médecine Hygiène. 2003;61:441–50.
Santos-Díaz G, Pérez-Pico AM, Suárez-Santisteban MÁ, García-Bernalt V, Mayordomo R, Dorado P. Prevalence of potential drug-drug interaction risk among chronic kidney disease patients in a Spanish hospital. Pharmaceutics. 2020;12:713.
Marquito AB, da Fernandes NMS, Colugnati FAB, de Paula RB, Marquito AB, da Fernandes NMS, et al. Interacoes medicamentosas potenciais em pacientes com doenca renal cronica. Braz J Nephrol. 2014;36:26–34.
Rama M, Viswanathan G, Acharya LD, Attur RP, Reddy PN, Raghavan SV. Assessment of drug-drug interactions among renal failure patients of nephrology ward in a south Indian tertiary care hospital. Indian J Pharm Sci. 2012;74:63.
Reidenberg MM. The biotransformation of drugs in renal failure. Am J Med. 1977;62:482–5.
Mallikaarjun S, Shoaf SE, Boulton DW, Bramer SL. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet. 2008;47:533–42.
Bauman JW, Antal JM, Adams LM, Johnson BM, Murray SC, Peng B, et al. Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist. Invest New Drugs. 2012;30:662–71.
Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol. 2002;53:21S-30S.
Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23:1258–70.
Yeung CK, Shen DD, Thummel KE, Himmelfarb J. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int. 2014;85:522–8.
Barnes KJ, Rowland A, Polasek TM, Miners JO. Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol. 2014;70:1097–106.
Velenosi TJ, Feere DA, Sohi G, Hardy DB, Urquhart BL. Decreased nuclear receptor activity and epigenetic modulation associates with down-regulation of hepatic drug-metabolizing enzymes in chronic kidney disease. FASEB J. 2014;28:5388–97.
Tsujimoto M, Sugimoto S, Nagatomo M, Furukubo T, Izumi S, Yamakawa T, et al. Possibility of decrease in CYP1A2 function in patients with end-stage renal disease. Ther Apher Dial. 2014;18:174–80.
Matsuo K, Yamamoto S, Wakamatsu T, Takahashi Y, Kawamura K, Kaneko Y, et al. Increased proinflammatory cytokine production and decreased cholesterol efflux due to downregulation of ABCG1 in macrophages exposed to indoxyl sulfate. Toxins. 2015;7:3155–66.
Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, et al. Role of NF-κB in Regulation of PXR-mediated gene expression A mechanism for the suppression of cytochrome P-450 3A4 BY proinflammatory agents. J Biol Chem. 2006;281:17882–9.
Watanabe H, Sugimoto R, Ikegami K, Enoki Y, Imafuku T, Fujimura R, et al. Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism. Biochem Pharmacol. 2017;145:192–201.
Dreisbach AW, Lertora JJL. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial. 2003;16:45–50.
Rowland-Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol. 2011;4:261–74.
Yoon S, Yi S, Rhee S, Lee HA, Kim Y, Yu K-S, et al. Development of a physiologically-based pharmacokinetic model for cyclosporine in Asian children with renal impairment. Transl Clin Pharmacol. 2019;27:107–14.
Lu C, Suri A, Shyu WC, Prakash S. Assessment of cytochrome P450-mediated drug–drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. Biopharm Drug Dispos. 2014;35:543–52.
Bergman A, Bi Y, Mathialagan S, Litchfield J, Kazierad DJ, Pfefferkorn JA, et al. Effect of hepatic organic anion-transporting polypeptide 1B INHIBITION AND CHRONIC KIDNEY DISEASE ON THE PHARMACOKINETICS OF A LIVER-TARGETED GLUCOKINASE ACTIVATOR: A MODEL-BASED EVALUATIOn. Clin Pharmacol Ther. 2019;106:792–802.
Steelandt J, Jean-Bart E, Goutelle S, Tod M. A prediction model of drug exposure in cirrhotic patients according to Child-Pugh classification. Clin Pharmacokinet. 2015;54:1245–58.
Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 Induction from in vivo information. Clin Pharmacokinet. 2008;47:669–80.
Tod M, Goutelle S, Clavel-Grabit F, Nicolas G, Charpiat B. Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions. Clin Pharmacokinet. 2011;50:519–30.
Gabriel L, Tod M, Goutelle S. Quantitative prediction of drug interactions caused by CYP1A2 inhibitors and inducers. Clin Pharmacokinet. 2016;55:977–90.
Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, Tod M, et al. In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates. AAPS J. 2013;15:415–26.
Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.
Rowland M, Matin SB. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm. 1973;1:553–67.
Nakazawa R, Kaneko M, Hoshi H, Kim T, Nakamura M, Azuma N, et al. Liver blood flow in chronic hemodialysis patients. Nephron. 1996;73:396–402.
Quantitative prediction of drug drug interactions-DDI-Predictor Academic version [Internet]. 2020. https://www.ddi-predictor.org/. Accessed 16 Dec 2020.
Hsu C-Y, Bates DW, Kuperman GJ, Curhan GC. Relationship between hematocrit and renal function in men and women. Kidney Int. 2001;59:725–31.
Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899–911.
Aparicio M, Chauveau P, Précigout VD, Bouchet J-L, Lasseur C, Combe C. Nutrition and outcome on renal replacement therapy of patients with chronic renal failure treated by a supplemented very low protein diet. J Am Soc Nephrol. 2000;11:708–16.
Rein - Analyse d’ordonnance [Internet]. SiteGPR. http://sitegpr.com/fr/rein/analyse-dordonnance/. Accessed 12 Feb 2021.
DrugBank | Pharmaceutical Knowledge Base | API Integrations [Internet]. https://www.drugbank.com/. Accessed 7 Jan 2021.
Abbas R, Hsyu P-H. Clinical pharmacokinetics and pharmacodynamics of bosutinib. Clin Pharmacokinet. 2016;55:1191–204.
Barbhaiya RH, Shukla UA, Pfeffer M, Pittman KA, Shrotriya R, Laroudie C, et al. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur J Clin Pharmacol. 1994;46:41–7.
Caccia S, Vigano GL, Mingardi G, Garattini S, Gammans RE, Placchi M, et al. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokinet. 1988;14:171–7.
Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig. 2014;34:845–55.
Tan W, Yamazaki S, Johnson TR, Wang R, O’Gorman MT, Kirkovsky L, et al. Effects of renal function on crizotinib pharmacokinetics: dose recommendations for patients with ALK-positive non-small cell lung cancer. Clin Drug Investig. 2017;37:363–73.
Nichols AI, Richards LS, Behrle JA, Posener JA, McGrory SB, Paul J. The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Ther. 2011;49:3–13.
Ravis WR, Reid S, Sica DA, Tolbert DS. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol. 2005;45:810–21.
Dunselman P, Edgar B, Scaf A, Kuntze C, Wesseling H. Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure. Br J Clin Pharmacol. 1989;28:45–52.
Larsson R, Karlberg BE, Gelin A, Åberg J, Regårdh C-G. Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. J Clin Pharmacol. 1990;30:1020–30.
Appel-Dingemanse S, Smith T, Merz M. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome. J Clin Pharmacol. 2002;42:312–8.
Sica DA, Marino MR, Hammett JL, Ferreira I, Gehr TWB, Ford NF. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther. 1997;62:610–8.
US Food and Drug Administration. Corlanor (Ivabradine) Drug Approval and database [Internet]. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206143orig1s000toc.cfm. Accessed 15 Oct 2022.
Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol. 1993;45:367–71.
US Food and Drug Administration. Lurasidone (Latuda) Drug Approval and Database [Internet]. 2010. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200603. Accessed 15 Oct 2010.
Vourvahis M, Fang J, Checchio T, Milton A, Weatherley B, McFadyen L, et al. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function. HIV Clin Trials. 2013;14:99–109.
Bateman DN, Gokal R, Dodd TRP, Blain PG. The pharmacokinetics of single doses of metoclopramide in renal failure. Eur J Clin Pharmacol. 1981;19:437–41.
Jordö L, Attman PO, Aurell M, Johansson L, Johnsson G, Regårdh C-G. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet. 1980;5:169–80.
Bui K, She F, Sostek M. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014;54:1375–82.
Neves DV, Lanchote VL, Neto MM, da Costa JAC, Vieira CP, Coelho EB. Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. Br J Clin Pharmacol. 2016;82:83–91.
Kleinbloesem CH, van Brummelen P, van Harten J, Danhof M, Breimer DD. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. Clin Pharmacol Ther. 1985;37:563–74.
Sayama H, Takubo H, Komura H, Kogayu M, Iwaki M. Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients. AAPS J. 2014;16:1018–28.
Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD. The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand. 1989;80:89–90.
Thyrum PT, James Wong Y, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:521–33.
Snoeck E, Van Peer A, Mannens G, Woestenborghs R, Heykants J, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology. 1995;122:223–9.
Gardin A, Dodman A, Kalluri S, Neelakantham S, Tan X, Legangneux E, et al. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study. Int J Clin Pharmacol Ther. 2017;55:54–65.
Torres R, Kramer WG, Baroldi P. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment. J Clin Pharmacol. 2015;55:525–33.
Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol. 2012;52:1388–98.
Shoaf SE, Bricmont P, Mallikaarjun S. Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int. 2014;85:953–61.
US Food and Drug Administration. Vardenafil (Levitra) Drug Approval and Database [Internet]. 2003. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra.cfm. Accessed 15 Oct 2022.
Troy SM, Schultz RW, Parker VD, Chiang ST, Blum RA. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther. 1994;56:14–21.
Boinpally R, Alcorn H, Adams MH, Longstreth J, Edwards J. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. Clin Drug Investig. 2013;33:199–206.
Yoshida K, Sun B, Zhang L, Zhao P, Abernethy DR, Nolin TD, et al. Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. Clin Pharmacol Ther. 2016;100:75–87.
Tan M-L, Yoshida K, Zhao P, Zhang L, Nolin TD, Piquette-Miller M, et al. Effect of chronic kidney disease on nonrenal elimination pathways: a systematic assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. Clin Pharmacol Ther. 2018;103:854–67.
Ghoneim AM, Mansour SM. The effect of liver and kidney disease on the pharmacokinetics of clozapine and sildenafil: a physiologically based pharmacokinetic modeling. Drug Des Devel Ther. 2020;14:1469–79.
Zhou J, You X, Ke M, Ye L, Wu W, Huang P, et al. Dosage adjustment for ceftazidime in pediatric patients with renal impairment using physiologically based pharmacokinetic modeling. J Pharm Sci. 2021;110:1853–62.
Romão Jr JE, Haiashi AR, Elias RM, Luders C, Ferraboli R, Castro MCM, et al. Positive acute-phase inflammatory markers in different stages of chronic kidney disease. Am J Nephrol. 2006;26:59–66.
US Food and Drug Administration. Pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labelling. 2020.
European Medicines Agency. Evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function [Internet]. 2016. https://www.ema.europa.eu/en/evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function. Accessed 15 Oct 2022.
Kimoto E, Vourvahis M, Scialis RJ, Eng H, Rodrigues AD, Varma MVS. Mechanistic evaluation of the complex drug-drug interactions of maraviroc: contribution of cytochrome P450 3A, P-glycoprotein and organic anion transporting polypeptide 1B1. Drug Metab Dispos. 2019;47:493–503.